Combination of MEK and CDK4/6 inhibitors in KRAS-positive pancreatic cancer induced cancer cell senescence and created a physiological stress response that activated endothelial cells and sensitized tumors to PD-1 checkpoint blockade (63). Here, KRAS is linked to pancreatic neoplasm.